Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting Conditions
Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the relative bioavailability of fluoxetine HCL 40
mg capsules (by Ranbaxy Laboratories Limited) with that of PROZAC® 40 mg capsules (by Dista
Products Company) following a single oral dose (1 x 40 mg capsule) in healthy, adult subjects
under fasting conditions